I Change Adherence & Raise Expectations

The iCARE study, a clustered-randomized controlled trial, is evaluating two adherence
promotion interventions for adolescents that Cystic Fibrosis (CF) care teams will implement.
Half the centers will receive the Comprehensive Adherence Program (CAP) for 2 years. CAP
consists of the Adherence Dashboard (a web-based resource offering automated and regularly
updated patient adherence estimates based on pharmacy refill patterns that is integrated
with health information abstracted from the CF Foundation-managed patient registry) AND
training in the CF My Way program (a validated problem-solving adherence promotion
intervention). The other half of the centers will receive the Adherence Dashboard only in
year 1 of the study and CAP in year 2 of the study. Participants are patients age 11-20
years old who are diagnosed with CF and have been prescribed at least one of the following
medications for at least 6 months prior to signing the informed consent: azithromycin,
hypertonic saline, Pulmozyme®, TOBI®, or inhaled compounded tobramycin. Rate of refilling
prescriptions is the primary outcome with lung function decline rates, exacerbation rates,
and patient reported measures including health related quality of life and CF knowledge and
skills, as secondary outcomes.